500 related articles for article (PubMed ID: 17897883)
1. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
2. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2008 Dec; 7(10):1557-67. PubMed ID: 19053211
[TBL] [Abstract][Full Text] [Related]
3. Vaccination procedures against Coxsackievirus-induced heart disease.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2003 Dec; 2(6):805-15. PubMed ID: 14711363
[TBL] [Abstract][Full Text] [Related]
4. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer.
Jiang Z; Xu W; Li K; Yue Y; Xu L; Ye F; Xiong S
J Gene Med; 2008 Aug; 10(8):918-29. PubMed ID: 18512734
[TBL] [Abstract][Full Text] [Related]
5. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
Yue Y; Xu W; Hu L; Jiang Z; Xiong S
Virology; 2009 Apr; 386(2):438-47. PubMed ID: 19233446
[TBL] [Abstract][Full Text] [Related]
6. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
8. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma.
Henke A; Jarasch N; Martin U; Zell R; Wutzler P
Viral Immunol; 2008 Mar; 21(1):38-48. PubMed ID: 18355121
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis.
Horwitz MS; La Cava A; Fine C; Rodriguez E; Ilic A; Sarvetnick N
Nat Med; 2000 Jun; 6(6):693-7. PubMed ID: 10835688
[TBL] [Abstract][Full Text] [Related]
11. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice.
Glück B; Schmidtke M; Merkle I; Stelzner A; Gemsa D
J Mol Cell Cardiol; 2001 Sep; 33(9):1615-26. PubMed ID: 11549341
[TBL] [Abstract][Full Text] [Related]
12. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
13. Blocking the CD40-CD40L interaction by CD40-Ig reduces disease progress in murine myocarditis induced by CVB3.
Bo H; Zhenhu L; Lijian Z
Cardiovasc Pathol; 2010; 19(6):371-6. PubMed ID: 19914091
[TBL] [Abstract][Full Text] [Related]
14. T lymphocyte responses in CVB3-induced murine myocarditis.
Huber S; Polgar J; Moraska A; Cunningham M; Schwimmbeck P; Schultheiss P
Scand J Infect Dis Suppl; 1993; 88():67-78. PubMed ID: 7685923
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis.
Park JH; Kim DS; Cho YJ; Kim YJ; Jeong SY; Lee SM; Cho SJ; Yun CW; Jo I; Nam JH
Vaccine; 2009 Mar; 27(13):1974-83. PubMed ID: 19168108
[TBL] [Abstract][Full Text] [Related]
16. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis.
Yuan J; Liu Z; Lim T; Zhang H; He J; Walker E; Shier C; Wang Y; Su Y; Sall A; McManus B; Yang D
Circ Res; 2009 Mar; 104(5):628-38. PubMed ID: 19168435
[TBL] [Abstract][Full Text] [Related]
17. Coxsackievirus B3-induced chronic myocarditis in outbred NMRI mice.
Merkle I; Tonew M; Glück B; Schmidtke M; Egerer R; Stelzner A
J Hum Virol; 1999; 2(6):369-79. PubMed ID: 10774554
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
19. CTLA4-Ig relieves inflammation in murine models of coxsackievirus B3-induced myocarditis.
Han B; Jiang H; Liu Z; Zhang Y; Zhao L; Lu K; Xi J
Can J Cardiol; 2012; 28(2):239-44. PubMed ID: 22336520
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization.
Yue Y; Gui J; Xu W; Xiong S
Mol Immunol; 2011 Jan; 48(4):706-13. PubMed ID: 21168219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
